51P Phase II Dose Expansion Study of DSP107, a First-in-class Fusion Protein Targeting CD47 and 4-1BB, in Combination with Atezolizumab in Patients with Advanced MSS Colorectal Cancer

A. Saeed, J. Zhang,B. Bashir,A. Philipovskiy, R. Chantre, S. Amsili, R. Tabakman, Y. Shwartz, A. Foley-Comer, A. Jimeno

Annals of Oncology（2024）

Cited 0|Views3

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined